Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

Journal:

The New England Journal of Medicine

Published:

2025-12-08

DOI:

10.1056/nejmoa2514752

Affiliations:

32

Authors:

35

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	11.000000 11.000000	0.31
Cleveland Clinic Taussig Cancer Center, United States of America (USA)	1.000000	0.03
Mount Sinai Medical Center (MSMC), United States of America (USA)	1.000000	0.03
Alberta Health Services (AHS), Canada	1.000000	0.03
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain	1.000000	0.03
Tel Aviv Sourasky Medical Center, Israel	1.000000	0.03
Johnson & Johnson, Japan, Japan	1.000000	0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.03
Mayo Clinic, United States of America (USA)	1.000000	0.03
Oregon Health and Science University (OHSU), United States of America (USA)	1.000000	0.03
Clínica Universidad de Navarra (CUN), UNAV, Spain	1.000000	0.03
The University of Texas MD Anderson Cancer Center, United States of America (USA)	1.000000	0.03
Royal Perth Hospital, Australia	1.000000	0.03
Levine Cancer Institute, Atrium Health, United States of America (USA)	1.000000	0.03
Asan Medical Center (AMC), South Korea	1.000000	0.03
Hadassah Medical Center, HUJI, Israel	1.000000	0.03
Tohoku University Hospital, Japan	1.000000	0.03
Japanese Red Cross Medical Center, Japan	1.000000	0.03
Johnson & Johnson Medical (China) Ltd., China	1.000000	0.03
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.03
Johnson & Johnson, Netherlands, Netherlands	1.000000	0.03
Colorado Blood Cancer Institute, United States of America (USA)	0.500000	0.01
Sarah Cannon Research Institute (SCRI), United States of America (USA)	0.500000	0.01
Chaim Sheba Medical Center at Tel HaShomer, Israel	0.500000	0.01
Tel Aviv University (TAU), Israel	0.500000	0.01
St Vincent's Hospital Melbourne, Australia	0.500000	0.01
The University of Melbourne (UniMelb), Australia	0.500000	0.01
Institute of Biomedical Research of Salamanca (IBSAL), Spain	0.250000	0.01
Cancer Research Center (CIC), Spain	0.250000	0.01
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.250000	0.01
Hospital Universitario de Salamanca (HUS), USAL, Spain	0.250000	0.01

Interested in Oncology and Carcinogenesis?